Long-term impact of the decrease of infliximab trough levels on the disease course in Inflammatory Bowel Disease patients under maintenance treatment with infliximab

被引：0
|
作者：
Orfanoudaki, E. [1 ]
Gazouli, M. [2 ]
Foteinogiannopoulou, K. [1 ]
Theodoraki, E. [1 ]
Legaki, E. [2 ]
Koutroubakis, I. [1 ]
机构：
[1] Univ Hosp Heraklion, Gastroenterol, Iraklion, Crete, Greece
[2] Natl & Kapodistrian Univ Athens, Dept Basic Med Sci, Lab Biol, Athens, Greece
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P408
引用
收藏
页码：S375 / S376
页数：2
相关论文
共 50 条
  • [21] Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues
    Caviglia, Renato
    Boskoski, Ivo
    Cicala, Michele
    EXPERT OPINION ON DRUG SAFETY, 2008, 7 (05) : 617 - 632
  • [22] Long-term treatment of inflammatory bowel disease associated spondyloarthropathy with infliximab.
    Antivalle, Marco
    Mutti, Alessandra
    Bertani, Luca
    Randisi, Giovanna
    Vulpio, Laura
    Ardizzone, Sandro
    Colombo, Elisabetta
    Carrabba, Mario
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S472 - S472
  • [23] The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease
    Hoekman, Daniel R.
    Brandse, Johannan F.
    de Meij, Tim G.
    Hummel, Thalia Z.
    Lowenberg, Mark
    Benninga, Marc A.
    D'Haens, Geert R.
    Kindermann, Angelika
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2015, 50 (09) : 1110 - 1117
  • [24] Infliximab trough levels are associated with disease activity in pediatric inflammatory bowel disease
    Hoekman, D. R.
    Brandse, J. F.
    de Meij, T. G.
    Hummel, T. Z.
    Lowenberg, M.
    Benninga, M. A.
    D'Haens, G. R. A. M.
    Kindermann, A.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S412 - S412
  • [25] Trough serum infliximab level, anti-infliximab antibody status and response to infliximab maintenance treatment in inflammatory bowel disease (IBD)
    Kong, J. Y.
    Bundell, C. S.
    Pawlik, J.
    Hollingsworth, P. N.
    Forbes, G. M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 59 - 60
  • [26] Long-term outcomes after primary infliximab treatment failure in patients with inflammatory bowel disease
    Buhl, S.
    Steenholdt, C.
    Borghede, M.
    Rasmussen, M.
    Brynskov, J.
    Thomsen, O. O.
    Ainsworth, M. A.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S287 - S288
  • [27] Long-Term Outcomes After Primary Infliximab Treatment Failure in Patients With Inflammatory Bowel Disease
    Buhl, Sine
    Steenholdt, Casper
    Borghede, Maria K.
    Rasmussen, Maria
    Brynskov, Jorn
    Thomsen, Ole
    Ainsworth, Mark A.
    GASTROENTEROLOGY, 2016, 150 (04) : S809 - S809
  • [28] Infliximab trough levels and anti-drug antibodies after induction predict long-term clinical remission in infliximab-treated patients with inflammatory bowel disease
    Bodini, G.
    Del Nero, L.
    Giannini, E. G.
    Tolone, S.
    De Bortoli, N.
    Anjali, J.
    Baldissarro, I.
    Savarino, V.
    Savarino, E.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S408 - S409
  • [29] Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients
    Eberl, Anja
    Huoponen, Saara
    Pahikkala, Tapio
    Blom, Marja
    Arkkila, Perttu
    Sipponen, Taina
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2017, 52 (12) : 1348 - 1353
  • [30] Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease
    Pariente, Benjamin
    de Chambrun, Guillaume Pineton
    Krzysiek, Roman
    Desroches, Marine
    Louis, Gauthier
    De Cassan, Chiara
    Baudry, Clotilde
    Gornet, Jean-Marc
    Desreumaux, Pierre
    Emilie, Dominique
    Colombel, Jean-Frederic
    Allez, Matthieu
    INFLAMMATORY BOWEL DISEASES, 2012, 18 (07) : 1199 - 1206
12345